Akers Biosciences, Inc. (NASDAQ: AKER) shares acquired 2.9% to $1.60, having signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company's flagship rapid tests for heparin-induced thrombocytopenia across GNYHA's network of over 300 member hospitals and health systems. Share volume was 3,500, compared to an all-day average of 44,800
